Literature DB >> 18627662

Managing tuberculosis and HIV in sub-Sahara Africa.

Umesh G Lalloo1, Sandy Pillay.   

Abstract

Tuberculosis (TB) and HIV represent a deadly duo in sub-Sahara Africa, a region most affected by both diseases. The HIV epidemic has aggravated already strained and frequently poorly performing TB control programs. These programs face numerous challenges, and novel, regionally appropriate solutions need to be developed. In the context of TB, some challenges include the rapid diagnosis of active TB in the face of paucibacillary lung disease and atypical presentations with HIV/AIDS, lack of clinical expertise, poor contact tracing, limited laboratory facilities, delayed recognition of drug-resistant TB, increased workload of health care workers, erratic drug supplies, inadequate isolation facilities, and environmental and personal protection in drug-resistant cases. Similar problems exist in the context of HIV but are aggravated by the need for complex antiretroviral drug regimens and lifelong treatment. Treating both conditions invites drug interactions and toxic effects that are common to both HIV and TB treatment and the vexing question of when to introduce antiretroviral treatment in subjects with active TB. Combining HIV and TB care has the potential to bring additional infrastructural and human resources to the respective programs, with synergistic benefits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627662     DOI: 10.1007/s11904-008-0021-5

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  27 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

Review 2.  Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care.

Authors:  Salim S Abdool-Karim; Quarraisha Abdool-Karim; Gerald Friedland; Umesh Lalloo; Wafaa M El-Sadr
Journal:  AIDS       Date:  2004-04-30       Impact factor: 4.177

3.  Tuberculosis in Africa--combating an HIV-driven crisis.

Authors:  Richard E Chaisson; Neil A Martinson
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

4.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Authors:  Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

Review 5.  Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade.

Authors:  R W Shafer; B R Edlin
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

6.  Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa.

Authors:  C Connolly; A Reid; G Davies; W Sturm; K P McAdam; D Wilkinson
Journal:  AIDS       Date:  1999-08-20       Impact factor: 4.177

Review 7.  Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.

Authors:  M P Hawken; D W Muhindi
Journal:  Int J Tuberc Lung Dis       Date:  1999-08       Impact factor: 2.373

8.  Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.

Authors:  Eline L Korenromp; Fabio Scano; Brian G Williams; Christopher Dye; Paul Nunn
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

9.  A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.

Authors:  Christopher Jack; Umesh Lalloo; Quarraisha Abdool Karim; Salim Abdool Karim; Wafaa El-Sadr; Sharon Cassol; Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-01       Impact factor: 3.731

10.  Tb drug resistance: is it really a threat to Africa?

Authors:  Paul Nunn; Matteo Zignol; Ernesto Jaramillo; Abigail Wright; Haileyesus Getahun
Journal:  Ethiop Med J       Date:  2007-10
View more
  10 in total

Review 1.  Obstacles and opportunities to improve antiretroviral regimen access in low-income countries.

Authors:  Jennifer Cohn; Brook Baker
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

Review 2.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

3.  Knowledge, attitudes, and practice of tuberculosis among Maasai in Simanjiro district, Tanzania.

Authors:  Pieter Jacob Haasnoot; Tijs Evert Boeting; Moignet Ole Kuney; Jos van Roosmalen
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings--insights from South Africa.

Authors:  Naomi S Levitt; Krisela Steyn; Joel Dave; Debbie Bradshaw
Journal:  Am J Clin Nutr       Date:  2011-11-16       Impact factor: 7.045

5.  The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Authors:  Rui Zhu; Jennifer J Kiser; Heiner I Seifart; Cedric J Werely; Charles D Mitchell; David Z D'Argenio; Courtney V Fletcher
Journal:  J Clin Pharmacol       Date:  2011-05-10       Impact factor: 3.126

6.  Loss of life expectancy due to respiratory infectious diseases: findings from the global burden of disease study in 195 countries and territories 1990-2017.

Authors:  Guogui Huang; Fei Guo
Journal:  J Popul Res (Canberra)       Date:  2022-02-07

7.  Yield of undetected tuberculosis and human immunodeficiency virus coinfection from active case finding in urban Uganda.

Authors:  J N Sekandi; J List; H Luzze; X-P Yin; K Dobbin; P S Corso; J Oloya; A Okwera; C C Whalen
Journal:  Int J Tuberc Lung Dis       Date:  2014-01       Impact factor: 2.373

8.  Towards understanding the drivers of policy change: a case study of infection control policies for multi-drug resistant tuberculosis in South Africa.

Authors:  Trust Saidi; Faatiema Salie; Tania S Douglas
Journal:  Health Res Policy Syst       Date:  2017-05-30

9.  Monitoring linked epidemics: the case of tuberculosis and HIV.

Authors:  María S Sánchez; James O Lloyd-Smith; Wayne M Getz
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

10.  A qualitative exploration of doctors and nurses experiences on the management of tuberculosis and HIV co-infection in a tuberculosis-HIV high burden community in northern KwaZulu-Natal, South Africa.

Authors:  Mbuso Precious Mabuza; Constance Shumba
Journal:  J Public Health Afr       Date:  2018-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.